Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N. Blackwell K, et al. Among authors: schwebig a. Ann Oncol. 2015 Sep;26(9):1948-1953. doi: 10.1093/annonc/mdv281. Epub 2015 Jun 28. Ann Oncol. 2015. PMID: 26122726 Free PMC article. Clinical Trial.
Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.
Becker P, Schwebig A, Brauninger S, Bialleck H, Luxembourg B, Schulz M, Tsamadou C, Wiesneth M, Reinhardt P, Mytilineos J, Seidl C, Gattu S, Kaliakina N, Singh P, Schrezenmeier H, Seifried E, Bonig H. Becker P, et al. Among authors: schwebig a. Transfusion. 2016 Dec;56(12):3055-3064. doi: 10.1111/trf.13853. Epub 2016 Sep 16. Transfusion. 2016. PMID: 27633122 Clinical Trial.
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.
Matucci-Cerinic M, Allanore Y, Kavanaugh A, Buch MH, Schulze-Koops H, Kucharz EJ, Woehling H, Babic G, Poetzl J, Davis A, Schwebig A. Matucci-Cerinic M, et al. Among authors: schwebig a. RMD Open. 2018 Nov 14;4(2):e000757. doi: 10.1136/rmdopen-2018-000757. eCollection 2018. RMD Open. 2018. PMID: 30487998 Free PMC article.
The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab.
Vogg B, Poetzl J, Schwebig A, Sekhar S, Kivitz A, Krivtsova N, Renner O, Body JJ, Eastell R. Vogg B, et al. Among authors: schwebig a. Clin Ther. 2024 Nov;46(11):916-926. doi: 10.1016/j.clinthera.2024.08.007. Epub 2024 Sep 17. Clin Ther. 2024. PMID: 39294041 Free article. Review.
20 results